Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Performance Update
JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ COVID-19 Antibody Microarray as a research-use-only (RUO) product in Europe and the US.
MosaiQ COVID-19 Antibody Microarray Performance
A summary of the interim study results using greater than 160 samples for the MosaiQ COVID-19 Antibody Microarray are set out below:
|Pathogen||Sensitivity %||Specificity %|
“While the test is now available for research use only, the Company will continue internal and external studies. We expect to achieve the CE Mark in the coming weeks, permitting broader distribution and use in Europe. Quotient also plans to seek emergency use authorization in the US, following guidelines established by the U.S. Food and Drug Administration (FDA). With FDA authorization, broader use would be permitted in the US as well,” said Franz Walt, Chief Executive Officer of Quotient.
About Quotient Limited
Building on 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using our MosaiQ technology to test for COVID-19 antibodies). The MosaiQ system has not yet been cleared by the FDA for sale in the United States. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceeding; continued or worsening adverse conditions in the general domestic and global economic markets, including the recent novel coronavirus (COVID-19) outbreak; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Contact: Peter Buhler, Chief Financial Officer, firstname.lastname@example.org; +41 22 545 52 26
Upcoming Life Sciences Events
- July 2020
- Florida: Evolution Summit
- Taipei: BIO Asia-Taiwan
- Digital RESI